RxDoctor Payments Data

David Hodgson, MD

General Practice · Washington, KSNPI 1902807522

Payments from drug & device makers

What this record shows

The money is spread across several categories — royalties or licence payments (57.0%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Smiths Medical ASD, Inc. accounts for 97.7% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2021 at $6,112 and has fallen 98.7% since, to $82 in 2025. Among general practice clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$18,422in general payments, 2019–2025

Across 36 payments — averaging $511.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smiths Medical ASD, Inc.$18K
  • AstraZeneca$106
  • AbbVie$83
  • Vapotherm Inc$58
  • Mylan Specialty L.p.$50
  • Amgen$29
  • plus $96 from 6 others

What the payments were for

  • Royalty or licence$10,50057%
  • Consulting fees$7,50041%
  • Food & beverage$4222%

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$18,422 in reported general payments places this provider in the 95th percentile of 771 general practice providers in Kansas.

See all general practice providers in Kansas

Medicare billing

Part B allowed, 2024
$56,342
Medicare patients
160
Services billed
552

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban63$48,872
OzempicSemaglutide28$26,017
JanuviaSitagliptin Phosphate16$14,095
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$10,223
AbrysvoRsv Vacc, Pref A And Pref B/Pf19$5,874
Metoprolol Succinate337$4,692
Atorvastatin Calcium401$4,566
Levothyroxine Sodium336$3,926
Duloxetine Hcl87$3,826
PremproEstrogen,con/M-Progest Acet13$3,089
Tamsulosin Hcl212$3,033
Rosuvastatin Calcium167$2,943
Pantoprazole Sodium285$2,928
Gabapentin129$2,894
Dexlansoprazole DrDexlansoprazole12$2,863

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo, Prempro, Premarin$16$60,444107 claims
AbbVieSynthroid$83$1,52629 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 771 general practice providers in Kansas.

Other general practice in Washington

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →